2-(5-(4-butylphenyl)-3-cyano-4,5-dimethylfuran-2(5H)-ylidene)malononitrile | 383124-88-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-(5-(4-butylphenyl)-3-cyano-4,5-dimethylfuran-2(5H)-ylidene)malononitrile
• 英文别名: 2-dicyanomethylene-3-cyano-4,5-dimethyl-5-[4'-n-butylphenyl]-2,5-dihydrofuran；2-[5-(4-Butylphenyl)-3-cyano-4,5-dimethyl-2(5H)-furanylidene]propanedinitrile；2-[5-(4-butylphenyl)-3-cyano-4,5-dimethylfuran-2-ylidene]propanedinitrile
• CAS: 383124-88-7
• 化学式: C₂₀H₁₉N₃O
• 分子量: 317.39
• InChiKey: FOFCIIMDQXFVOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  80.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-hydroxy-3-[4'-n-butylphenyl]-2-butanone 、 丙二腈 在 乙醇锂 作用下， 以 四氢呋喃 为溶剂， 以69.1%.的产率得到2-(5-(4-butylphenyl)-3-cyano-4,5-dimethylfuran-2(5H)-ylidene)malononitrile
  参考文献：
  名称：

  COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX

  摘要：

  揭示了与GPR35及/或GPR35-hERG信号复合物在病理生理上相关的疾病的预防和/或治疗的组合物和方法。例如，揭示了用于预防和/或治疗与GPR35在受试者中病理生理相关的疾病的化合物。这些化合物具有以下公式(I)、(II)或(III)：

  公开号：

  US20120022116A1

文献信息

• Novel chromophores for polymeric thin films and optical waveguides and devices comprising the same
  申请人：CORNING INC.

  公开号：EP1772459A2

  公开（公告）日：2007-04-11

  The invention is directed to chromophores having novel electron withdrawing groups and novel bivalent cyclic bridges and to optical waveguides and optical devices having polymeric thin films which contain the novel chromophores.

  本发明涉及具有新型退电子基团和新型二价环桥的发色团，以及具有包含新型发色团的聚合物薄膜的光波导和光学设备。
• MOLECULES RELATED hERG Ion CHANNELS AND THE USE THEREOF
  申请人：Corning Incorporated

  公开号：EP2519236A2

  公开（公告）日：2012-11-07
• MOLECULES RELATED hERG ION CHANNELS AND THE USE THEREOF
  申请人：Deng Huayun

  公开号：US20120329865A1

  公开（公告）日：2012-12-27

  Disclosed are compounds having structural formula (I, II) or a pharmaceutically acceptable sale, solvate, clathrate, or prodrug thereof, wherein R 1 , R 2 , R 3 , R 6 , R 5 , and R 4 are defined herein. These compounds can be useful as therapeutic agents for modulating hERG ion channels, and for improving prevention and treatment of hERG associated cardiac repolarization disorders.
• [EN] MOLECULES RELATED hERG Ion CHANNELS AND THE USE THEREOF<br/>[FR] MOLÉCULES ASSOCIÉES À DES CANAUX IONIQUES HERG ET LEUR UTILISATION
  申请人：CORNING INC

  公开号：WO2011081970A2

  公开（公告）日：2011-07-07

  Disclosed are compounds having structural formula (I, II) or a pharmaceutically acceptable sale, solvate, clathrate, or prodrug thereof, wherein R1, R2, R3, R6, R5, and R4 are defined herein. These compounds can be useful as therapeutic agents for modulating hERG ion channels, and for improving prevention and treatment of hERG associated cardiac repolarization disorders.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE TROUBLES PATHOLOGIQUES ASSOCIÉS À GPR35 ET/OU AU COMPLEXE GPR35-HERG
  申请人：CORNING INC

  公开号：WO2012012278A2

  公开（公告）日：2012-01-26

  Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject.